Unique ID issued by UMIN | C000000090 |
---|---|
Receipt number | R000000132 |
Scientific Title | The Japan Working Group for the Assessment That the Alpha-glucosidase-inhibitor Blocks Cardiac Events in Patients With Myocardial Infarction and IGT |
Date of disclosure of the study information | 2005/08/31 |
Last modified on | 2018/05/22 10:36:01 |
The Japan Working Group for the Assessment That the Alpha-glucosidase-inhibitor Blocks Cardiac Events in Patients With Myocardial Infarction and IGT
ABC Study
The Japan Working Group for the Assessment That the Alpha-glucosidase-inhibitor Blocks Cardiac Events in Patients With Myocardial Infarction and IGT
ABC Study
Japan |
Patients With Myocardial Infarction and IGT
Cardiology | Endocrinology and Metabolism |
Others
NO
To evaluate whether alpha-glucosidase inhibitor, a drug for the supression postprandial hyperglycemia, could reduce the recurrence of myocardial infarction in patients with IGT and old myocardial infarction.
Efficacy
1.Cardiovascular mortality
2.Hospitalization due to cardiovascular events
(1) All cause mortality
(2) Hospitalization due to coronary artery disease
(3) Progression of IGT to diabetes
(4) Development or deterioration of either hypertension or hyperlipidemia
(5) Deterioraion of renal function
(6) Hospitalization due to cerebrovascular disease
(7) Hospitalization due to heart failure
Interventional
Parallel
Randomized
Cluster
Open -no one is blinded
Active
2
Prevention
Medicine |
In the voglibose group, voglibose will be prescribed at 0.6mg three times daily.
In control group, each participated doctor will instruct patients on a weight reduction or weight maintenance diet, and encouraged them to exercise regularly.
20 | years-old | <= |
100 | years-old | >= |
Male and Female
1.Impaired Glucose Tolerance
2.History of myocardial infarction
1.Type I diabetes
2.History of coronary artery bypass graft
3.Severe liver and/or kidney dysfunction
4.History of allergic response to drugs
5.arteriosclerosis obliterans
1570
1st name | |
Middle name | |
Last name | Masafumi Kitakaze |
National Cardiovascular Center
Cardiovascular Division
5-7-1 Fujishirodai, Suita City, Osaka Pref. 565-8565, Japan
06-6833-5012
kitakaze@zf6.so-net.ne.jp
1st name | |
Middle name | |
Last name | Masafumi Kitakaze |
Clinical Study Support Center Japan (CSSCJ)
ABC office
5-7-1 Fujishirodai, Suita Osaka 565-8565, JAPAN
06-6836-5012
http://www.csscj.com
kitakaze@zf6.so-net.ne.jp
National Cardiovascular Center
Grants in Health and Labour Sciences Research from the Ministry of Health, Labour and Welfare, Japan.
Japanese Governmental office
NO
2005 | Year | 08 | Month | 31 | Day |
Published
https://www.ncbi.nlm.nih.gov/pubmed/28779371
The age, ratio of males, and HbA1C were 65 vs. 65 years, 86 vs. 87%, and 5.6 vs. 5.5% in the groups with and without voglibose, respectively. Voglibose improved IGT; however, Kaplan-Meier analysis showed no significant between-group difference with respect to cardiovascular events [12.5% with voglibose vs. 10.1% without voglibose for the primary endpoint (95% confidence interval, 0.82-1.86)]; there were no significant differences in secondary endpoints.
Completed
2004 | Year | 11 | Month | 01 | Day |
2005 | Year | 04 | Month | 01 | Day |
2012 | Year | 06 | Month | 30 | Day |
2012 | Year | 06 | Month | 30 | Day |
2013 | Year | 06 | Month | 30 | Day |
2015 | Year | 02 | Month | 28 | Day |
2005 | Year | 08 | Month | 29 | Day |
2018 | Year | 05 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000000132
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |